Disease · MONDO_0001708

pulmonary sarcoidosis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. pulmonary sarcoidosis. Diseases, record MONDO_0001708. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001708

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: pulmonary sarcoidosis; Open Targets
Open Targets ID: MONDO_0001708; Open Targets
Other names: Sarcoidosis, Pulmonary, lung sarcoidosis, sarcoidosis of lung; Open Targets
Disease Ontology: DOID:13406; Disease Ontology
MeSH: D017565; MeSH
NCI Thesaurus: C34997; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 5 of its 30 drugs, from ClinicalTrials.gov; Open Targets

Drugs30

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PREDNISONE	CHEMBL635	Small molecule	Phase 3	ClinicalTrials.gov	4	4	3	Drugs and targets
METHYLPREDNISOLONE	CHEMBL650	Small molecule	Phase 3	ClinicalTrials.gov	3	3	1	Drugs and targets
HYDROXYCHLOROQUINE	CHEMBL1535	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
PREDNISOLONE	CHEMBL131	Small molecule	Phase 3	ClinicalTrials.gov	2	2	0	Drugs and targets
MYCOPHENOLIC ACID	CHEMBL866	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
AZITHROMYCIN	CHEMBL529	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
5-(4-((2S,5S)-5-(4-CHLOROBENZYL)-2-METHYLMORPHOLINO)PIPERIDIN-1-YL)-1H-1,2,4-TRIAZOL-3-AMINE	CHEMBL4788866	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ATORVASTATIN	CHEMBL1487	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
BOSENTAN	CHEMBL957	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 30

See all 30 drugs

Targets92

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	11	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
ADORA2A	Adenosine A2 receptor	1	Adenosine A2 receptor antagonist	Phase 2	https://conductscience.org/library/genes/135	Drugs and targets
ADORA2B	Adenosine A2 receptor	1	Adenosine A2 receptor antagonist	Phase 2	https://conductscience.org/library/genes/136	Drugs and targets
CHRNA4	Neuronal acetylcholine receptor; alpha4/beta2	1	Neuronal acetylcholine receptor; alpha4/beta2 agonist	Phase 1/2	https://conductscience.org/library/genes/1137	Drugs and targets
CHRNB2	Neuronal acetylcholine receptor; alpha4/beta2	1	Neuronal acetylcholine receptor; alpha4/beta2 agonist	Phase 1/2	https://conductscience.org/library/genes/1141	Drugs and targets
COXFA4	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2	https://conductscience.org/library/genes/4697	Drugs and targets
COXFA4L2	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2	https://conductscience.org/library/genes/56901	Drugs and targets
CSF1	Macrophage colony-stimulating factor 1	1	Macrophage colony-stimulating factor 1 inhibitor	Phase 2	https://conductscience.org/library/genes/1435	Drugs and targets
CSF2	Granulocyte-macrophage colony-stimulating factor	1	Granulocyte-macrophage colony-stimulating factor inhibitor	Phase 2	https://conductscience.org/library/genes/1437	Drugs and targets
EDNRA	Endothelin receptor, ET-A/ET-B	1	Endothelin receptor, ET-A/ET-B antagonist	Phase 2	https://conductscience.org/library/genes/1909	Drugs and targets

1 to 10 of 92

See all 92 targets

Trials16

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT05314517	A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis	Phase 2	107	2025-09-12	Sarcoidosis, Pulmonary	NAMILUMAB	Its record names the disease	ClinicalTrials.gov
NCT02024555	Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis	Phase 2	97	2020-07-09	Sarcoidosis; Antimycobacterial Therapy	AZITHROMYCIN, ETHAMBUTOL, LEVOFLOXACIN, RIFAMPIN	Its record names the disease	ClinicalTrials.gov
NCT00279708	Atorvastatin to Treat Pulmonary Sarcoidosis	Phase 2	55	2016-08-12	Sarcoidosis, Pulmonary	ATORVASTATIN	Its record names the disease	ClinicalTrials.gov
NCT02265874	Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot Study	Phase 1/2	50	2025-04-24	Sarcoidosis	(+/-)NICOTINE, NICOTINE	Its record names the disease	ClinicalTrials.gov
NCT03793439	Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis	Phase 1	5	2022-02-18	Sarcoidosis, Pulmonary, Sarcoidosis Lung, Sarcoidosis	PREDNISONE, TOFACITINIB	Its record names the disease	ClinicalTrials.gov
NCT05247554	Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary Sarcoidosis	Phase 3	200		Pulmonary Sarcoidosis	HYDROXYCHLOROQUINE, PREDNISONE	Its record names the disease	ClinicalTrials.gov
NCT00001877	Treatment of Pulmonary Sarcoidosis With Pentoxifylline	Phase 2	100		Pulmonary Sarcoidosis	PENTOXIFYLLINE	Its record names the disease	ClinicalTrials.gov
NCT06205121	Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis	Phase 2	96		Pulmonary Sarcoidosis	5-(4-((2S,5S)-5-(4-CHLOROBENZYL)-2-METHYLMORPHOLINO)PIPERIDIN-1-YL)-1H-1,2,4-TRIAZOL-3-AMINE	Its record names the disease	ClinicalTrials.gov
NCT02200146	Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS).	Phase 3	94		Pulmonary Sarcoidosis	HYDROXYCHLOROQUINE	Its record names the disease	ClinicalTrials.gov
NCT00701207	Study of Nicotine Patches in Patients With Sarcoidosis	Early phase 1	64		Pulmonary Sarcoidosis	(+/-)NICOTINE, NICOTINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 16

See all 16 trials

Comparisons in its trials7

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Namilumab vs Placebo: Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the DB Period	49 of 52	51 of 54	106	NCT05314517	Trial comparisons
Concomitant Levaquin, Ethambutol, Azithromycin and Rifampin vs Placebo: deaths from any cause	0 of 49	0 of 48	97	NCT02024555	Trial comparisons
Concomitant Levaquin, Ethambutol, Azithromycin and Rifampin vs Placebo: serious adverse events	4 of 49	3 of 48	97	NCT02024555	Trial comparisons
Concomitant Levaquin, Ethambutol, Azithromycin and Rifampin vs Placebo: Failure of Standard Therapy	3 of 43	2 of 48	91	NCT02024555	Trial comparisons
Intervention Group (Atorvastatin) vs Control Group (Placebo): serious adverse events	12 of 27	16 of 28	55	NCT00279708	Trial comparisons
Treatment vs Control: deaths from any cause	0 of 24	0 of 26	50	NCT02265874	Trial comparisons
Treatment vs Control: serious adverse events	0 of 24	0 of 26	50	NCT02265874	Trial comparisons

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
34029565	RESULT	1	PubMed
33089005	RESULT	1	PubMed
41819539	DERIVED	1	PubMed
33825964	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001708

GET https://conductscience.org/api/diseases/v1/MONDO_0001708/drugs?page=2

API reference For AI assistants